ARTICLE | Emerging Company Profile
Dimension's intentions
Dimension maximizing full capsids for more potent, safer gene therapy
May 25, 2015 7:00 AM UTC
With an industry veteran at the helm and its lead program partnered and paid for, Dimension Therapeutics Inc. aims to develop safer and more potent gene therapies by packaging as many gene copies into capsids as possible.
Dimension debuted in 2013 with a series A round and an option to NAV vector technology from RegenxBio Inc. Dimension has since exercised the option to license exclusive, worldwide rights to a portfolio of liver-targeted AAV vectors for up to eight programs. Dimension's four disclosed programs all use the RegenxBio vectors...